


Safety and efficacy of statin therapy in patients with stroke: A systematic review and meta-analysis

Oliver J. Ziff, Gargi Banerjee, Gareth Ambler, David J. Werring

Online Appendix


<i>eFigure 1: Systematic review flow diagram</i>	2
<i>eFigure 2: Meta-regression analyses in patients with previous ischemic stroke</i>	3
<i>eTable 1: Description of studies</i>	4
<i>eTable 2: Detailed characteristics of studies</i>	7
<i>eTable 3: Risk of Bias Assessment (Observational Studies)</i>	11
<i>eTable 4: Risk of Bias Assessment (Randomised Studies)</i>	13
<i>eTable 5: Meta-regression of all outcomes by stroke subtype</i>	14
<i>References for appendix</i>	15

eFigure 1: Systematic review flow diagram



Biffi et al. provides outcomes for both previous intracerebral hemorrhage and previous ischemic stroke subgroups.¹

eFigure 2: Meta-regression analyses in patients with previous ischemic stroke



All analyses that provided data on intracerebral hemorrhage rates were included. See Online Table 3 for statistical methods. Each circle represents a particular study, with the circle size dependent on the precision of each estimate in a random-effects model (the inverse of its variance). A. The risk of bias in each study was summated across all six domains (low risk=0, unclear risk=1, high risk=2; excluding the "other threats to validity" domain from the Cochrane risk of bias tool). $P = 0.017$. B. $P = 0.002$. C. $P = 0.03$

eTable 1: Description of studies

Study	Design	Population	Setting	Statin n	Control n	Follow-up duration (months)
Sacks 1996* ²	Randomised trial	MI with normal cholesterol	CARE	2081	2078	60
LIPID 1998* ³	Randomised trial	MI or unstable angina with normal cholesterol	LIPID	4512	4502	73.2
Plehn 1999 ⁴	Randomised trial	Prior stroke	CARE	111	100	60
White 2000 ⁵	Randomised trial	Prior stroke or TIA	LIPID	327	374	73.2
HPS 2002* ⁶	Randomised trial	Arterial disease or diabetes	HPS	10269	10267	60
Collins 2004 ⁷	Randomised trial	Ischemic stroke, TIA, CEA	HPS	1645	1635	60
Amarenco 2006 ⁸	Randomised trial	Stroke or TIA	SPARCL	2365	2366	58.8
Alvarez-Sabin 2007 ⁹	Retrospective cohort	Prior tPA for ischemic stroke	Barcelona database	36	109	3
Blanco 2007 ¹⁰	Randomised trial	Ischemic stroke	Santiago trial	43	46	3
Kennedy 2007 ¹¹	Randomised trial	TIA or minor stroke	FASTER	199	193	3
Montaner 2008 ¹²	Randomised trial	Acute ischemic stroke	MISTICS	28	28	3
FitzMaurice 2008 ¹³	Retrospective cohort	Primary ICH	Massachusetts database	79	150	22.92
Goldstein 2008 ¹⁴	Randomised trial	Previous ICH	SPARCL	45	48	58.8
Arnold 2009 ¹⁵	Retrospective cohort	Prior tPA for ischemic stroke	Swiss database	56	255	3
Goldstein 2009* ¹⁶	Randomised trial	Any previous stroke	SPARCL	2365	2366	58.8
Leker 2009 ¹⁷	Retrospective cohort	Prior stroke	Israeli database	31	62	60
Meier 2009 ¹⁸	Retrospective cohort	Prior tPA for ischemic stroke	Swiss database	55	256	3
Milionis 2009 ¹⁹	Retrospective cohort	Acute ischemic stroke	Athenian Stroke registry	198	596	42
Restrepo 2009 ²⁰	Prospective cohort	prior tPA for ischemic stroke	California database	66	75	3
Amarenco 2009 ²¹	Randomised trial	Previous ICH	SPARCL	45	48	58.8
Tapia-Perez 2009 ²²	Retrospective cohort	Previous ICH	Mexico database	18	57	1
Asberg 2010 ²³	Retrospective cohort	Prior stroke	Swedish database	5289	9240	3
Biffi 2011 ¹	Prospective cohort	Ischemic stroke or TIA	Massachusetts database	48	69	3
	Prospective cohort	Previous ICH	Massachusetts database	17	28	3

Study	Design	Population	Setting	Statin n	Control n	Follow-up duration (months)
Cappellari 2011 ²⁴	Retrospective cohort	Prior tPA for ischemic stroke	Italian database	105	73	3
Muscari 2011 ²⁵	Randomised trial	Acute ischemic stroke	Bologna trial	31	31	3
Ni Chroinin 2011 ²⁶	Prospective cohort	Acute ischemic stroke	North Dublin stroke study	246	189	12
Uchiyama 2011 ²⁷	Randomised trial	Prior ischemic stroke	JASAP study	647	647	12
Hackam 2012 ²⁸	Retrospective cohort	Acute ischemic stroke	Ontario database	8936	8936	50.4
Hjalmarsson 2012 ²⁹	Prospective cohort	Acute ischemic stroke	Swedish database	400	399	12
Tsai 2012 ³⁰	Retrospective cohort	Acute ischemic stroke	Chinese hospital	50	50	3
Yeh 2012 ³¹	Prospective cohort	Acute ischemic stroke or TIA with infection	Taiwan database	121	393	3
Dowlatshahi 2012 ³²	Retrospective cohort	Previous ICH	Canadian stroke network	616	1850	6
Cappellari 2013 ³³	Prospective cohort	Prior tPA for ischemic stroke	THRaST study	839	1233	3
Phipps 2013 ³⁴	Retrospective cohort	Acute ischemic stroke	Hartford database	334	470	1
Chen 2013 ³⁵	Retrospective cohort	Previous ICH	ESC congress abstract	859	9947	24
Niewada 2013 ³⁶	Retrospective cohort	Previous ICH	Polish registry	535	2576	1
Tapia-Perez 2013 ³⁷	Retrospective cohort	Previous ICH	Magdeburg	29	149	6
Winkler 2013 ³⁸	Retrospective cohort	Spontaneous ICH	Connecticut Stroke Centre	190	236	12
Al-Khaled 2014 ³⁹	Prospective cohort	Acute ischemic stroke	German database	7535	5012	3
Scheitz (low dose) 2014 ⁴⁰	Prospective cohort	Prior tPA for ischemic stroke	German multicentre	120	1129	3
Scheitz (med dose) 2014 ⁴⁰	Prospective cohort	Prior tPA for ischemic stroke	German multicentre	134	1129	3
Scheitz (high dose) 2014 ⁴⁰	Prospective cohort	Prior tPA for ischemic stroke	German multicentre	63	1129	3
Song 2014 ⁴¹	Retrospective cohort	Acute ischemic stroke	China Registry	3231	4224	3
Flint 2014 ⁴²	Retrospective cohort	ICH defined by ICD-9 (431) and CT	Kaiser Permanente	1194	2287	1
Pan 2014 ⁴³	Retrospective cohort	ICH defined by WHO criteria	China Registry	220	2998	12
Chang 2015 ⁴⁴	Retrospective cohort	Prior TIA	Taiwan database	12555	12556	39.6
Scheitz 2015 ⁴⁵	Retrospective cohort	Prior tPA for ischemic stroke	German database	5	398	3
Asberg 2015 ⁴⁶	Retrospective cohort	Previous ICH	Swedish registry	1097	4985	37.2

Study	Design	Population	Setting	Statin n	Control n	Follow-up duration (months)
Chen 2015 ⁴⁷	Retrospective cohort	ICH defined by ICD-9	Taiwan registry	749	7583	24
Tapai-Perez 2016 ⁴⁸	Retrospective cohort	Hypertensive or anticoagulant related ICH	Mexican database	45	278	12
Schmidt 2016 ⁴⁹	Retrospective cohort	Previous ICH	Danish registry	2258	13012	36
Lee 2017 ⁵⁰	Retrospective cohort	Ischemic stroke	Taiwan database	36798	8353	3
Siddiqui 2017 ⁵¹	Retrospective cohort	ICH with 3 month status known	ERICH	825	1632	3

[†] Study not included in meta-analysis. CARE, cholesterol and recurrent events trial; CEA, carotid endarterectomy; ERICH, ethnic variations in the risk, presentation and outcomes of intracerebral hemorrhage; FASTER, Fast assessment of stroke and transient ischemic attack to prevent early recurrence; HPS, heart protection study; ICD, international classification of diseases; ICH, intracerebral hemorrhage; JASAP, Japanese Aggrenox; LIPID, Long term prevention with pravastatin in ischemic disease; MI, myocardial infarction; MISTICS, multicentre clinical trial to study the safety and efficacy of simvastatin in the acute phase of ischemic stroke; SPARCL, Stroke prevention by aggressive reduction in cholesterol levels; THRaST; thrombolysis and statins study; TIA, transient ischemic attack; tPA, tissue plasminogen activator; WHO, world health organisation.

eTable 2: Detailed characteristics of studies

Study	Age		Male %		Smoker %		Diabetes %		Hyper-tension %		Hyper-lipidemia %		Atrial Fibrillation %		Coronary Artery Disease %		Anti-coagulation %		Anti-platelet %		
	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	
Plehn 1999 ⁴			86	86	16.2	16.1	13.6	14.6	42.0	43.2											
White 2000 ⁵	62	62	83	83	9	10	9	9	41	42	100	100			64	64	2	2	82	87.2	
Collins 2004 ⁷																					
Amarenco 2006 ⁸	63	62.5	60	59	19.1	19.3	16.7	16.9	62.4	61.4							5.9	6.5	87.4	100	
Alvarez-Sabin 2007 ⁹	70.5	71.8	54	52	10.5	26	34.6	15.5	69.2	48.6	96.2	18.2	34.6	34.6	57.7	8.2					
Blanco 2007 ¹⁰	69.7	66.5	54	48			37.2	34.8	53.8	63	93	100	11.6	11.6							
Kennedy 2007 ¹¹	66.6	69.8	53	44	25.3	24.2	12.1	6.3	51.5	57.9	9.1	6.3	1	1	7.1	9.5			100		
Montaner 2008 ¹²	74.8	70.5	51	51	28	28	26	26	61	61	16	16	27	27							
FitzMaurice 2008 ¹³																				32	
Goldstein 2008 ¹⁴	62.1	63.6	60	69	15.6	10.4	6.7	8.3	73.3	81.3										16	
Arnold 2009 ¹⁵													45	45							
Leker 2009 ¹⁷	70.9	72.8	47	45	14	9.7	44.3	26	87.6	83.6	87.6	14.6	19.5	19.5			71	41	55.7	32	
Meier 2009 ¹⁸	67.3	61.9	67	54	17	23	20.4	12.9	92.6	56.5			32.7	32.7	60	36.7	7.3	6.6	65.5		
Milionis 2009 ¹⁹	67	66.8	70	67	40.4	39.1	28.8	35.4	68.1	73.8	33.8	25.3	12.1	12.1	22.7	24.1				5.3	

Study	Age		Male %		Smoker %		Diabetes %		Hyper-tension %		Hyper-lipidemia %		Atrial Fibrillation %		Coronary Artery Disease %		Anti-coagulation %		Anti-platelet %	
	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C
Restrepo 2009 ²⁰	69	66	60	47	16	21	7	7	80	63	60	21	25	25	30	28	10	10	50	
Amarengo 2009 ²¹	62.1	63.6	60	69	15.6	10.4	6.7	8.3	73.3	81.3										40
Tapia-Perez 2009 ²²	62.7	66.9	44	40	11.1	12.7	27.8	22.8	88.3	66.7							5.6	0	5.6	42.5
Asberg 2010 ²³																				
Biffi 2011 ¹	74.2	72	42	48			32	20	88	76			30	30	42	15	38	19	60	
Cappellari 2011 ²⁴			56	58	33.3	16.4	20	13.7	80	68.5	60	11	6	6	25	11			44	
Muscari 2011 ²⁵	74.9	75.6	26	39	12.9	19.4	25.8	16.1	87.1	96.8	29	25.8								77.3
Ni Chroinin 2011 ²⁶	72	70	48	53	30	70	25	11	70	84	50	37	50	50	35	21	75	53		40
Uchiyama 2011 ²⁷																				
Biffi 2011 ¹	74.2	72	42	48			32	20	88	76			30	30	42	15	38	19	60	
Hackam 2012 ²⁸	77.9	77.9	47	46			25	26	80	80					26	27				
Hjalmarsson 2012 ²⁹																				
Tsai 2012 ³⁰	63.2	63	64	66			34	40	76	74					2	4				31.7
Yeh 2012 ³¹	73.3	74.3	47	49	31	30	60	50	80	74			17	17	26	18				39.8
Dowlatshahi 2012 ³²																				

Study	Age		Male %		Smoker %		Diabetes %		Hyper-tension %		Hyper-lipidemia %		Atrial Fibrillation %		Coronary Artery Disease %		Anti-coagulation %		Anti-platelet %	
	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C
Cappellari 2013 ³³	67.3	66.1	60	57	24.9	23.9	17.5	16	71	57.3			17.4	17.4					41.1	
Phipps 2013 ³⁴	85.8	86.8	38	35			31.7	17.4	87.4	82.3	79	24.5	57.8	57.8	57.2	36.8	28.7	23.2	62	2.01
Chen 2013 ³⁵	63	63	63	63																
Niewada 2013 ³⁶																				
Tapia-Perez 2013 ³⁷	72.24	69.55	55	52			44.8	26.1	93.1	69.1			34.4	34.4	3.4	4.03	31.03	18.1	3.4	36.8
Winkler 2013 ³⁸	70.4	67	50	49			29.5	15.7	82.1	71.2	64.7	17.4			39.5	22.9	19.5	15.3		36.8
Al-Khaled 2014 ³⁹	72.6	73.2	54	47			29	21	89	77	82	14	27	27			26	34		36.8
Scheitz (low dose) 2014 ⁴⁰	76	74	57	51	17.5	21.1	27.5	17.5	90	73.2			40	40	43.3	15.6	9	4.2	63.3	81.7
Scheitz (med dose) 2014 ⁴⁰	73	74	68	51	15.7	21.1	28.4	17.5	91	73.2			30.6	30.6	37.3	15.6	5	4.2	78.2	
Scheitz (high dose) 2014 ⁴⁰	73	74	71	51	22.2	21.1	27	17.5	90.5	73.2			33.3	33.3	49.1	15.6	1	4.2	85.5	8
Song 2014 ⁴¹	64.2	64.5	62	61	40.4	39.1	20	16.4	60.7	54.5			4.8	4.8	11.1	12.8			94.7	
Flint 2014 ⁴²	73.8	73.4	52	49			39.9	24.3	92.2	81.7			44.4	44.4	37	18.8				
Pan 2014 ⁴³	60.7	62.2	61	61	38.6	37.5	13.6	8	79.6	66.8	14.6	5.8	2.3	2.3	8.6	8.1	2.3	0.8	11.8	

Study	Age		Male %		Smoker %		Diabetes %		Hyper-tension %		Hyper-lipidemia %		Atrial Fibrillation %		Coronary Artery Disease %		Anti-coagulation %		Anti-platelet %		
	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	S	C	
Chang 2015 ⁴⁴																					21.3
Scheitz 2015 ⁴⁵	75	74	52	50	22.9	23.7	36.1	21.9	95.2	80.4	73.2	38.9	38.6	38.6	39.8	15.8					
Asberg 2015 ⁴⁶																					
Chen 2015 ⁴⁷	59	63	60	64			21.1	20.1	54.1	49.8	18.3	9	2.3	2.3	11.7	11.9	2.4	1.9	21.1		
Tapai-Perez 2016 ⁴⁸																					
Schmidt 2016 ⁴⁹																					
Lee 2017 ⁵⁰	65.1	65.6	57	56			50	49.6	84.1	84.6											87.2
Siddiqui 2017 ⁵¹	65.1	60.3	60	57			39.2	21.5	91	80.4	69.7	27.3					16.7	8.4	10.9		

* Studies not included in meta-analysis. S, statin cohort; C, control cohort; n/s, not specified.

eTable 3: Risk of Bias Assessment (Observational Studies)

Study	Selection of participants	Confounding variables	Measurement of exposure	Blinding of outcome	Incomplete outcome data	Selective reporting
Alvarez-Sabin 2007 ⁹	Low	High	High	High	Unclear	Low
FitzMaurice 2008 ¹³	Low	Low	Low	Unclear	Unclear	Unclear
Arnold 2009 ¹⁵	Low	Unclear	Unclear	Low	Unclear	Unclear
Leker 2009 ¹⁷	Unclear	Low	Unclear	Low	High	Unclear
Meier 2009 ¹⁸	Unclear	Low	Low	Unclear	Low	Unclear
Milionis 2009 ¹⁹	Unclear	Unclear	High	Low	Unclear	Unclear
Restrepo 2009 ²⁰	High	Unclear	Unclear	Unclear	High	Unclear
Tapia-Perez 2009 ²²	High	Unclear	Unclear	Unclear	Unclear	Unclear
Asberg 2010 ²³	Low	Low	High	Unclear	Unclear	Low
Biffi 2011 ¹	Low	Low	High	Low	Low	Unclear
Cappellari 2011 ²⁴	High	Low	High	Low	High	Unclear
Ni Chroinin 2011 ²⁶	High	Low	Unclear	Low	Unclear	Low
Biffi 2011 ¹	Unclear	Low	Low	Unclear	Unclear	Unclear
Hackam 2012 ²⁸	High	Low	High	Low	Unclear	High
Hjalmarsson 2012 ²⁹	High	Unclear	High	High	Low	Unclear
Tsai 2012 ³⁰	High	Unclear	High	Low	Unclear	Unclear
Yeh 2012 ³¹	Unclear	Unclear	Low	High	Low	High
Dowlatshahi 2012 ³²	Low	Low	Unclear	Unclear	Low	Low
Cappellari 2013 ³³	High	Low	High	Low	High	High
Phipps 2013 ³⁴	Unclear	Low	High	Low	Unclear	Unclear
Chen 2013 ³⁵	Unclear	Unclear	Low	Unclear	Unclear	Unclear

Study	Selection of participants	Confounding variables	Measurement of exposure	Blinding of outcome	Incomplete outcome data	Selective reporting
Niewada 2013 ³⁶	Unclear	Low	Low	Low	Unclear	Unclear
Tapia-Perez 2013 ³⁷	Unclear	Low	Unclear	Unclear	Unclear	Low
Winkler 2013 ³⁸	Unclear	Low	Unclear	Unclear	Low	Unclear
Al-Khaled 2014 ³⁹	High	Low	Unclear	Low	Unclear	Low
Scheitz (low dose) 2014 ⁴⁰	Unclear	Low	Unclear	Low	Unclear	Unclear
Scheitz (med dose) 2014 ⁴⁰	Unclear	Low	Unclear	Low	Unclear	Unclear
Scheitz (high dose) 2014 ⁴⁰	Unclear	Low	Unclear	Low	Unclear	Unclear
Song 2014 ⁴¹	High	Unclear	Unclear	High	Unclear	Unclear
Flint 2014 ⁴²	High	Low	Low	Unclear	Low	Unclear
Pan 2014 ⁴³	Low	Low	Low	Unclear	Low	High
Chang 2015 ⁴⁴	Low	High	Low	Low	Low	Unclear
Scheitz 2015 ⁴⁵	Unclear	Low	Unclear	Low	Unclear	Low
Asberg 2015 ⁴⁶	Unclear	Unclear	Low	Unclear	Unclear	Unclear
Chen 2015 ⁴⁷	High	Low	Unclear	Unclear	Unclear	Low
Tapai-Perez 2016 ⁴⁸	Unclear	Low	Unclear	Unclear	Unclear	High
Schmidt 2016 ⁴⁹	Low	Low	Unclear	Unclear	Low	Unclear
Lee 2017 ⁵⁰	High	Low	High	Low	High	Unclear
Siddiqui 2017 ⁵¹	Low	Low	Low	High	Unclear	Low

Risk of bias reported for each domain using the Risk of Bias Assessment Tool for Non-randomized Studies (RoBANS).

eTable 4: Risk of Bias Assessment (Randomised Studies)

Study	Sequence Generation	Allocation Concealment	Blinding of Personnel	Blinding of outcome	Incomplete outcome data	Selective reporting	Other threats to validity
Plehn 1999 ⁴	Unclear	Low	Low	Low	Low	Low	Low
White 2000 ⁵	Unclear	Low	Low	Low	Low	Low	Low
Collins 2004 ⁷	Low	Low	Low	Low	Low	Low	Low
Amarenco 2006 ⁸	Low	Low	Low	Low	Low	Low	Low
Blanco 2007 ¹⁰	Low	Low	Low	Unclear	Low	Low	Low
Kennedy 2007 ¹¹	Low	Low	Low	Low	Low	Low	Low
Montaner 2008 ¹²	Low	Low	Low	Low	Unclear	Low	Low
Goldstein 2008 ¹⁴	Low	Low	Low	Low	Low	Low	Low
Amarenco 2009 ²¹	Low	Low	Low	Low	Low	Low	Low
Muscari 2011 ²⁵	Low	Low	Low	Low	Unclear	Low	Low
Uchiyama 2011 ²⁷	Unclear	Low	Low	Low	Low	Unclear	Unclear

Risk of bias reported for each domain using the Cochrane risk of bias assessment tool.

eTable 5: Meta-regression and sensitivity analyses of all outcomes by stroke subtype

Outcome	Summary bias score	Difference between statin and control arms at baseline					Baseline study-level variable		RCT vs observational
		Hyperlipidemia	Diabetes	Hypertension	Anti-coagulation	Antiplatelets	Year of publication	Male gender	
Previous intracerebral hemorrhage									
Intracerebral hemorrhage (n=3)	0.84 (0.10-6.98) p = 0.48	n/a	n/a	n/a	n/a	n/a	0.89 (0.31-2.54) p = 0.38	n/a	3.73 (0.83-17.0); 1.02 (0.89-1.16)
Ischemic stroke (n=1)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Any stroke (n=1)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
All-cause mortality (n=15)	1.00 (0.72-1.37) p = 0.98	1.00 (0.076-1.33) p = 0.94	0.94 (0.86-1.02) p = 0.14	0.97 (0.89-1.05) p = 0.40	1.04 (0.92-1.19) p = 0.44	1.06 (0.92-1.22) p = 0.31	0.80 (0.67-0.94) p = 0.01	0.85 (0.78-0.93) p = 0.003	1.03 (0.47-2.23); 0.46 (0.33-0.63)
Poor functional outcome (n=7)	1.01 (0.76-1.33) p = 0.94	1.00 (0.90-1.11) p = 0.84	1.01 (0.89-1.15) p = 0.79	1.03 (0.91-1.16) p = 0.50	1.04 (0.99-1.10) p = 0.07	1.03 (0.93-1.14) p = 0.37	0.94 (0.82-1.07) p = 0.26	0.95 (0.81-1.11) p = 0.39	n/a
Previous ischemic stroke									
Intracerebral hemorrhage (n=11)	0.85 (0.74-0.96) p = 0.017	0.97 (0.96-0.99) p = 0.002	1.06 (0.94-1.19) p = 0.28	1.02 (0.98-1.08) p=0.28	0.83 (0.66-1.05) p = 0.10	1.03 (0.99-1.06) p = 0.15	0.95 (0.84-1.07) p = 0.35	1.08 (1.01-1.16) p = 0.03	1.73 (1.20-2.49); 1.28 (0.85-1.93)
Ischemic stroke (n=3)	0.98 (0.83-1.15) p = 0.34	n/a	n/a	n/a	n/a	n/a	0.99 (0.89-1.09) p = 0.34	n/a	0.80 (0.70-0.92); 0.69 (0.62-0.77)
Any stroke (n=7)	0.95 (0.89-1.01) p = 0.09	0.92 (0.72-1.17) p = 0.26	1.10 (0.99-1.21) p = 0.06	1.01 (0.84-1.21) p = 0.90	n/a	n/a	0.98 (0.93-1.03) p = 0.38	1.06 (0.89-1.26) p = 0.44	0.92 (0.80-1.05); 0.58 (0.36-0.94)
All-cause mortality (n=13)	0.88 (0.76-1.01) p = 0.07	0.99 (0.96-1.02) p = 0.52	1.03 (0.96-1.10) p=0.42	1.03 (0.99-1.06) p = 0.10	0.99 (0.89-1.10) p = 0.79	1.02 (0.97-1.06) p = 0.32	0.95 (0.82-1.10) p = 0.45	1.00 (0.93-1.08) p = 1.00	1.04 (0.87-1.24); 0.60 (0.42-0.85)
Poor functional outcome (n=19)	0.96 (0.89-1.04) p = 0.32	1.00 (1.00-1.01) p = 0.38	1.01 (0.98-1.04) p=0.62	1.00 (0.99-1.02) p = 0.64	1.02 (0.99-1.06) p = 0.15	1.00 (0.98-1.02) p = 0.87	0.99 (0.91-1.06) p = 0.70	0.99 (0.96-1.02) p = 0.47	0.77 (0.51-1.15); 0.83 (0.75-0.92)

The primary assessment utilised the residual maximum likelihood using random-effects weighting and the Knapp and Hartung t-distribution. β -coefficient with corresponding 95% CI for natural logarithm of effect size for each variable of interest reflecting a unit-change. n/a; not applicable due to insufficient data.

References for appendix

1. Biffi A, Devan WJ, Anderson CD, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. *Neurology* 2011;76:1581-8.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;335:1001-9.
3. LIPID. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;339:1349-57.
4. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. *Circulation* 1999;99:216-23.
5. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. *N Engl J Med* 2000;343:317-26.
6. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7-22.
7. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative G. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004;363:757-67.
8. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355:549-59.
9. Alvarez-Sabin J, Huertas R, Quintana M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. *Stroke* 2007;38:1076-8.
10. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. *Neurology* 2007;69:904-10.
11. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. *Lancet Neurol* 2007;6:961-9.
12. Montaner J, Chacon P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. *Eur J Neurol* 2008;15:82-90.
13. FitzMaurice E, Wendell L, Snider R, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. *Stroke* 2008;39:2151-4.
14. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. *Neurology* 2008;70:2364-70.
15. Prior statin use, intracranial hemorrhage and outcome after intra-arterial thrombolysis for acute ischemic stroke. 18th European Stroke Conference; 2009; Stockholm, Sweden.
16. Goldstein LB, Amarenco P, Zivin J, et al. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *Stroke* 2009;40:3526-31.
17. Leker RR, Khoury ST, Rafaeli G, et al. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). *Stroke* 2009;40:2581-4.

18. Meier N, Nedeltchev K, Brekenfeld C, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. *Stroke* 2009;40:1729-37.
19. Millionis HJ, Giannopoulos S, Kosmidou M, et al. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. *Neurology* 2009;72:1816-22.
20. Restrepo L, Bang OY, Ovbiagele B, et al. Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy. *Cerebrovasc Dis* 2009;28:384-90.
21. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. *Stroke* 2009;40:1405-9.
22. Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, et al. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. *Cent Eur Neurosurg* 2009;70:15-20.
23. Asberg S, Henriksson KM, Farahmand B, et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register. *Stroke* 2010;41:1338-42.
24. Cappellari M, Deluca C, Tinazzi M, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. *J Neurol Sci* 2011;308:128-34.
25. Muscari A, Puddu GM, Santoro N, et al. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. *Clin Neuropharmacol* 2011;34:141-7.
26. Ni Chroinin D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. *Stroke* 2011;42:1021-9.
27. Uchiyama S, Ikeda Y, Urano Y, Horie Y, Yamaguchi T. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. *Cerebrovasc Dis* 2011;31:601-13.
28. Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. *Arch Neurol* 2012;69:39-45.
29. Hjalmarsson C, Bokemark L, Manhem K, Mehlig K, Andersson B. The effect of statins on acute and long-term outcome after ischemic stroke in the elderly. *Am J Geriatr Pharmacother* 2012;10:313-22.
30. Tsai NW, Lee LH, Huang CR, et al. The association of statin therapy and high-sensitivity C-reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke. *Clin Chim Acta* 2012;413:1861-5.
31. Yeh PS, Lin HJ, Chen PS, et al. Effect of statin treatment on three-month outcomes in patients with stroke-associated infection: a prospective cohort study. *Eur J Neurol* 2012;19:689-95.
32. Dowlathshahi D, Demchuk AM, Fang J, et al. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. *Stroke* 2012;43:1518-23.
33. Cappellari M, Bovi P, Moretto G, et al. The THRoMbolysis and STatins (THRaST) study. *Neurology* 2013;80:655-61.
34. Phipps MS, Zeevi N, Staff I, Fortunato G, Kuchel GA, McCullough LD. Stroke severity and outcomes for octogenarians receiving statins. *Arch Gerontol Geriatr* 2013;57:377-82.
35. Early statin therapy reduces all-cause mortality in acute hemorrhagic stroke patients without prior statin use. European Society of Cardiology, ESC Congress 2013 2013; Amsterdam Netherlands. *European Heart Journal*.

36. Niewada M, Skowronska M, Sarzynska-Dlugosz IM, Kaminski B, Kobayashi A, Czlonkowska A. Pharmacotherapy prior to and in acute haemorrhagic stroke. The use of pharmacotherapy and drugs associated outcomes in real-world practice - findings from the Polish Hospital Stroke Registry. *Neurol Neurochir Pol* 2013;47:517-24.
37. Tapia-Perez JH, Rupa R, Zilke R, Gehring S, Voellger B, Schneider T. Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. *Neurosurg Rev* 2013;36:279-87; discussion 87.
38. Winkler J, Shoup JP, Czap A, et al. Long-term improvement in outcome after intracerebral hemorrhage in patients treated with statins. *J Stroke Cerebrovasc Dis* 2013;22:e541-5.
39. Al-Khaled M, Matthis C, Eggers J. Statin treatment in patients with acute ischemic stroke. *Int J Stroke* 2014;9:597-601.
40. Scheitz JF, Seiffge DJ, Tutuncu S, et al. Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. *Stroke* 2014;45:509-14.
41. Song B, Wang Y, Zhao X, et al. Association between statin use and short-term outcome based on severity of ischemic stroke: a cohort study. *PLoS One* 2014;9:e84389.
42. Flint AC, Conell C, Rao VA, et al. Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition. *JAMA Neurol* 2014;71:1364-71.
43. Pan YS, Jing J, Wang YL, et al. Use of statin during hospitalization improves the outcome after intracerebral hemorrhage. *CNS Neurosci Ther* 2014;20:548-55.
44. Chang CH, Lin CH, Caffrey JL, et al. Risk of Intracranial Hemorrhage From Statin Use in Asians: A Nationwide Cohort Study. *Circulation* 2015;131:2070-8.
45. Scheitz JF, Endres M, Heuschmann PU, Audebert HJ, Nolte CH. Reduced risk of poststroke pneumonia in thrombolysed stroke patients with continued statin treatment. *Int J Stroke* 2015;10:61-6.
46. Statin therapy and the risk of death and recurrent intracerebral hemorrhage. International Journal of Stroke Conference: European Stroke Organisation Annual Conference 2015; Glasgow United Kingdom.
47. Chen PS, Cheng CL, Chang YC, Kao Yang YH, Yeh PS, Li YH. Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. *Eur J Neurol* 2015;22:773-80.
48. Tapia-Perez JH, Zilke R, Schneider T. Match-study of statin therapy in spontaneous intracerebral hemorrhage: is the discontinuation reasonable? *J Neurosurg Sci* 2016;60:301-12.
49. Schmidt LB, Goertz S, Wohlfahrt J, Melbye M, Munch TN. Recurrent Intracerebral Hemorrhage: Associations with Comorbidities and Medicine with Antithrombotic Effects. *PLoS One* 2016;11:e0166223.
50. Lee M, Saver JL, Wu YL, et al. Utilization of Statins Beyond the Initial Period After Stroke and 1-Year Risk of Recurrent Stroke. *J Am Heart Assoc* 2017;6.
51. Siddiqui FM, Langefeld CD, Moomaw CJ, et al. Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. *Stroke* 2017;48:2098-104.